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Abstract
Background: Pain emerges as a challenge in the treatment of leprosy patients. In this study, we describe the
prevalence and type of pain in patients with leprosy, and its effect on patients’ quality of life in an endemic area of
Northeast Brazil.
Findings: A cross-sectional survey of 260 patients attending leprosy reference centres in Sergipe, Northeast Brazil
was conducted. Individuals were assessed for the presence and type of pain, skin sensory loss, peripheral nerve
enlargement, touch and pinprick sensations, mechanical allodynia and nerve palpation. Participants completed the
Douleur Neuropathique 4 questionnaire, and we also used the Brief Pain Inventory scale and the World Health
Organization Quality of Life-BREF instrument to arrive at our results. One hundred and ninety-five (75 %) patients
reported pain, mostly of the neuropathic type. Pain was moderate in 84 (43.1 %) and severe in 94 (48.2 %) participants.
The presence of pain was associated with disability (p = 0.001), leprosy reactions (p = 0.004) and lower quality of life.
Most patients with neuropathic pain were treated with steroids, despite their low efficacy for this type of pain.
Conclusion: Pain is highly prevalent among leprosy patients and is associated with low quality of life. Leprosy
management should include a systematic assessment of the type of pain a patient experiences in order to provide
adequate treatment.
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Background
More than 250,000 new leprosy cases are reported annu-
ally worldwide [1]. Leprosy is a infections disease that
causes significant skin and peripheral nerve impairment,
physical disability and deformity [2, 3]. Although there is
a widespread perception that sensory losses preclude pa-
tients to perceive pain [3, 4], this is a frequent complaint
of patients attending leprosy treatment centres in Brazil.
The presence of pain affects physical and emotional
wellbeing; leads to social isolation, relationship and psy-
chological problems, and an inability to work [5]; and
increases health service consultations for patients. System-
atic evaluation of adverse effects and type of pain and its
effect on quality of life (QoL) is needed to increase aware-
ness and encourage the development of appropriate lep-
rosy management interventions. The concept of QoL
denotes the impact that an illness or injury has on a per-
son’s wellbeing. It includes physical and psychological
health, social relationships and a person’s interaction with
the environment [6].
In this report, we describe the prevalence and type of
pain in leprosy patients, and the effect that pain has on
patients’ QoL in an endemic area of Brazil.
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Methods
A cross-sectional survey of patients aged >15 years who
attended the University Hospital Leprosy Clinic and the
Leprosy and Tuberculosis Reference Centre in Aracaju
was conducted. These are the two leprosy reference cen-
tres in Sergipe, Northeast Brazil. All consecutive patients
who visited the centres between February and June
2015, who were receiving multidrug therapy for leprosy
or who had been previously treated for leprosy and were
returning to the centres for follow-up, were invited to
participate. Patients with diabetes, those who drank
excessive amounts of alcohol, those who were known to
be HIV positive, or those who had mental and physical
conditions that could interfere with the assessment of
pain were excluded.
Participants were interviewed using a structured ques-
tionnaire to obtain demographic and clinical information,
disability grade, QoL, and the presence and intensity of
pain in the three months leading up to enrolment in the
study. Leprosy was classified as paucibacillary or multiba-
cillary (MB), and as tuberculoid, borderline, lepromatous
or as having an indeterminate clinical presentation, using
the World Health Organization (WHO) classification [7].
Nerves were considered to be affected in the presence of
pain or nerve thickening on palpation, loss of sensitivity
with the monofilament test or motor impairment [8]. Lep-
rosy reactions were defined as episodes of acute inflamma-
tion of skin lesions or nerves (type 1), or the appearance
of inflamed cutaneous nodules with/without neuritis
(type 2) [7]. Disability grades were assessed using the
WHO International Classification of Functioning, Dis-
ability and Health: grade 0 indicates that there is no
loss of sensation or deformity, grade 1 denotes loss of
sensation without deformity, and grade 2 refers to loss
of sensitivity and deformities [2, 9].
Individuals were appraised for skin sensory losses and
enlargement of peripheral nerves by assessing touch,
pinprick sensations, mechanical allodynia and palpation
of nerves. Patients completed the Douleur Neuropathi-
que 4 questionnaire in Portuguese [10]. Scores ≥4 were
classified as neuropathic pain. We also used the Brief
Pain Inventory scale to define pain intensity and the
level of the worst pain a patient had experienced the
week before enrolment in the study. Scores ranged from 0
to 10, with higher scores indicating greater pain severity
and its interference with general activity, walking, mood,
sleep, work, interpersonal relations and life enjoyment
[11]. Quality of life was evaluated using the WHOQoL-
BREF questionnaire, which involves four domains (phys-
ical health, psychological health, social relationships and
environment) [6].
Sample size was calculated to detect a difference of 20 %
in the QoL between cases with and without pain, with α =
5 % and 80 % power. We hypothesised that two-thirds of
patients would experience pain, and that a patient with pain
would be more likely to have low QoL (60 % and 40 % of
patients with and without pain, respectively). A sample size
of 260 patients (195 who had pain) was required to exam-
ine this hypothesis.
The WHO analysis syntax for SPSS Statistics software
package version 20.0 (IBM Corporation, Armonk, NY)
was used to calculate QoL scores. The chi-square test
was used to compare discrete variables of patients with
and without pain. Variables associated with pain in the
bivariate analysis were entered into logistic regression
models using backwards-stepwise procedures. The
Mann–Whitney U test was used to assess differences be-
tween QoL domains, and Spearman’s correlation coeffi-
cients were used to describe the relationship between
pain intensity and QoL. P-values <5 % were considered
to be statistically significant.
The study was approved by the Human Research Ethics
Committee at the Federal University of Sergipe (CAAE:
31078114.3.0000.5546). Informed written consent was ob-
tained from all participants. Parents or guardians provided
written informed consent for minors.
Results
Two hundred and sixty patients were enrolled in the
study, with 195 (75.0 %) experiencing pain, as shown in
Table 1. One hundred and sixty-six (85.1 %) patients with
pain had neuropathic pain and 29 (14.9 %) had nociceptive
pain. Patients with pain were more likely to be MB (p =
0.03), live in rural areas (41/195 vs. 5/65, p = 0.01), and ex-
perience disability (adjusted odds ratio [aOR] = 2.8; 95 %
confidence interval [CI] = 1.5–5.3; p = 0.001) and leprosy
reactions (aOR = 2.5; 95 % CI = 1.3–4.8; p = 0.004). Lep-
rosy reactions were present in 68 % (113/166) of patients
with neuropathic pain and 58.6 % (17/29) of patients with
nociceptive pain. The pain intensity was moderate in 84
(43.1 %) and severe in 94 (48.2 %) patients. Participants
with neuropathic pain had higher pain intensity than those
with nociceptive pain [median (interquartile range, IQR),
8 (5–10) vs. 5 (4–7), p < 0.001]. Pain affected participants’
general activities (140, 71.8 %), mood (105, 53.8 %), walk-
ing ability (98, 50.2 %), work (146, 74.9 %) and sleep (105,
53.8 %). A significant correlation was observed between
pain severity and the perception of limitations (p < 0.001).
Patients with neuropathic pain had been prescribed steroids
(126, 75.9 %), analgesics (30, 18.1 %) or anti-inflammatories
(10, 6.0 %), but only 28 % of all patients experiencing pain
reported that the treatment improved it.
The QoL scores in patients experiencing pain were
lower in the physical health (p < 0.001), psychological
health (p < 0.001) and environment (p < 0.001) domains
than patients without pain, and patients with neuro-
pathic pain had the lowest scores for all domains (see
Table 1). Patients with neuropathic pain had lower QoL
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scores than patients with nociceptive pain in the physical
health and psychological health domains (see Table 2).
Pain intensity was associated with decreasing QoL
in the physical health (r = −0.34; p < 0.001), psycho-
logical health (r = −0.23; p = 0.003), social relation-
ships (r = −0.15; p = 0.03) and environment (r = −0.32;
p < 0.001) domains.
Discussion
Pain is highly prevalent among patients with leprosy and
the presence of pain is associated with low QoL. There
is a well-established association between the severity of
the disease (in terms of the number of lesions), deform-
ities and stigma, and low QoL [12, 13]. It has been re-
ported that patients with functional limitations scored
lower in the QoL assessment in the physical health and
environment domains [7]. Pain decreases psychological
[5, 14] and mental wellbeing [2, 9], affects mood and
often leads to depression, restricts activities, affects a
person’s work and disrupts sleep [15].
In this study, patients with neuropathic pain had lower
QoL than patients without pain. This is in contrast to
another study that reported that neuropathic pain
mostly affects patients in the physical health domain [5].
Perhaps the differences between our study and the other
report therefore can be explained by the epidemiological
context such as the characteristics of patients being
enrolled in the studies and differences in the cultural
Table 1 Characteristics and WHOQoL-BREF domain scores of study participants
Variables Pain p-value
Yes (n = 195) No (n = 65)
Age, median (IQR) 49 (36–59) 44 (37–61) 0.94**
Sex, male, n (%) 120 (61.5) 41 (63.1) 0.82*
Rural area, n (%) 41 (21.0) 5 (7.7) 0.01*
MB leprosy, n (%) 159 (81.5) 45 (69.2) 0.03*
Clinical form
Indeterminate 21 (12.2) 7 (11.7) 0.56*
Tuberculoid 31 (18.0) 16 (26.7)
Borderline 52 (30.2) 16 (26.7)
Lepromatous 68 (39.5) 21 (35.0)
>2 affected nerves, n (%) 37 (18.9) 10 (15.4) 0.51*
Disability, n (%) 131 (67.2) 25 (38.5) <0.001*
Leprosy reaction, n (%) 130 (66.7) 27 (41.5) <0.001*
Type 1 reaction, n (%) 75 (38.5) 15 (23.1) 0.04*
Type 2 reaction, n (%) 55 (28.2) 12 (18.5) 0.16*
WHOQoL-BREF domains
Physical health, median (IQR) 50.0 (35.7–64.3) 71.4 (64.3–76.8) <0.001**
Psychological health, median (IQR) 66.7 (58.3–75.0) 75.0 (66.7–79.2) <0.001**
Social relationships, median (IQR) 75.0 (58.3–75.0) 75.0 (66.7–75.0) 0.11**
Environment, median (IQR) 56.3 (46.9–65.6) 62.5 (54.7–68.8) <0.001**
Neuropathic pain Yes (n = 166) No (n = 65)
WHOQoL-BREF domains
Physical health, median (IQR) 46.4 (32.1–58.0) 71.4 (64.3–76.8) <0.001**
Psychological health, median (IQR) 57.3 (66.7–75.0) 75.0 (66.7–79.2) <0.001**
Social relationships, median (IQR) 66.4 (58.3–75.0) 75.0 (66.7–75.0) 0.04**
Environment, median (IQR) 46.9 (46.9–63.3) 62.5 (54.7–68.8) <0.001**
*Chi-square test; **Mann–Whitney U test




pain (n = 166)
Nociceptive




46.4 (32.1–58.0) 60.7 (48.2-71.4) <0.001
Psychological health,
median (IQR)
57.3 (66.7–75.0) 70.8 (62.5-79.1) 0.04
Social relationships,
median (IQR)
66.4 (58.3–75.0) 71.4 (66.7-75.0) 0.17
Environment,
median (IQR)
46.9 (46.9–63.3) 59.4 (53.1-68.7) 0.18
*Mann–Whitney U test
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and socioeconomic context, including the availability of
long term rehabilitation and support programmes.
Neuropathic pain had a higher prevalence in this study
than expected; most studies report that it’s prevalent in
11 % to 70 % of patients [3–5, 9, 14–16]. This could be
explained by the selection of patients in referral centres.
In Brazil, uncomplicated cases are diagnosed and treated
in health centres and only patients with complications,
reactions or disabilities are transferred to referral centres.
In the present study, the presence of leprosy reactions
was associated with pain, as previously reported by others
[3, 9]. Although it is debatable what it is exactly that deter-
mines the predominant type of pain in a patient, nocicep-
tive pain seems to be elicited by hyperexcitation of intact
nociceptive fibres, and neuropathic pain is likely due to
the persistence of immune-mediated reactions in the som-
atosensory system of peripheral nerves [3]. The use of ste-
roids is considered to be effective for nociceptive pain, but
not for neuropathic pain [3, 9, 14]. However, most patients
with neuropathic pain in our study had been treated with
steroids, highlighting the urgent need to identify the type
of pain for appropriate selection of treatment. Pain man-
agement is a key component of patient clinical manage-
ment and has a direct effect on a patient’s QoL [2].
Our study had several limitations. Firstly, we did not
investigate QoL changes over time. The analysis was
limited to referred patients, who would have had a
higher frequency of complications than those treated at
health centres, thus overstating the prevalence of pain
among leprosy patients. Our findings therefore reflect
the magnitude of the problem of patients attending
reference centres like the ones in Brazil.
Conclusion
Pain is a frequent co-morbidity associated with low QoL in
leprosy patients. All leprosy patients should be systematic-
ally evaluated to identify the presence and type of pain so
that appropriate clinical management can be applied. Lon-
gitudinal studies are needed to describe changes in the oc-
currence and type of pain over the course of treatment and
rehabilitation, and its impact on QoL. Because neuropathic
pain is very common in leprosy patients and because it has
a greater impact on a patient’s QoL than nociceptive pain,
this highlights the need for research to identify efficacious
treatments appropriate for specific types of pain.
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